anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Erlotinib
Trial phase: Not Applicable
ATC code: L01EB02 | L01XE03
SMILES: C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 44
Group description: Patients will be instructed to take tablets once daily.Patients will begin treatment with erlotinib 150 mg (1 tablet) orally daily on day -14 and it will be continued for a total of 15 days, through day 0.The day of planned surgical resection of the invasive breast cancer will be considered day 0.
Eligibility criteria:
DISEASE CHARACTERISTICS:

Inclusion

Cytologically or histologically confirmed adenocarcinoma of the breast

Stage I-III disease
BI-RADS 4 or 5 abnormalities on breast imaging and undergoing core needle biopsy for diagnosis
Participants must have a lesion of at least 1-cm on breast imaging studies (mammogram, ultrasound, or MRI)

Participants must have breast cancer amenable to surgery with curative intent and must have agreed to undergo such surgery

The surgical procedure must be scheduled in the near future to accommodate a treatment period of no less and no more than 15 days
Clinically positive for the overexpression of EGFR and interleukin-1α

Clinically negative for expression of the estrogen receptor (ER-negative) and progesterone receptor (PgR-negative)

May be positive or negative for HER2

Exclusion

Locally advanced or metastatic disease not amenable to surgery
Known brain metastases

PATIENT CHARACTERISTICS:

Inclusion

Female
Menopausal status not specified
ECOG performance status (PS) 0-2 or Karnofsky PS 60-100%
ANC ≥ 1000/mm³
Platelet count ≥ 75,000/mm³
AST and ALT ≤ 2.5 times upper limits of normal (ULN)
Alkaline phosphatase ≤ 2.5 times ULN
Bilirubin ≤ 2 times ULN
Hemoglobin > 9 g/dL
Creatinine within normal institutional limits OR creatinine clearance >60 mL/min
Negative serum pregnancy test within 7 days of enrollment for pre-menopausal women and women within 6 months of menopause
Women of child-bearing potential and their partners must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation

Exclusion

Pregnant or nursing
History of allergic reactions attributed to compounds of similar chemical or biologic composition to erlotinib hydrochloride

Uncontrolled intercurrent illness including, but not limited to, any of the following:

Ongoing or active infection
Symptomatic congestive heart failure
Unstable angina pectoris
Cardiac arrhythmia
Psychiatric illness/social situations that would limit compliance with study requirements

PRIOR CONCURRENT THERAPY:

Exclusion

Received any other therapy (i.e., surgery, radiation, hormone treatment, biologic therapy, and/or chemotherapy) for the treatment of breast cancer
Concurrent use of anti-neoplastic or anti-tumor agents not part of the study therapy, including chemotherapy, radiation therapy, immunotherapy, and hormonal anticancer therapy
Receiving any other investigational agents
Intervention: Warfarin
Trial phase: Phase 2
ATC code: B01AA03
SMILES: CC(=O)CC(c1ccccc1)c1c(O)c2ccccc2oc1=O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 250
Group description: warfarin tablets

warfarin: warfarin tablets
Eligibility criteria:
Inclusion Criteria:

Male or female, 18 to 80 years old.
Able to provide written informed consent.
Persistent non-valvular AF supported by abnormal electrocardiogram (ECG)
A congestive heart failure, hypertension, age ≥ 75 years, diabetes, and prior stroke (CHADS2) index score of at least 2

Exclusion Criteria:

Subjects with mitral valve disease or previous valvular heart surgery
Known contraindication to any anticoagulant including vitamin K antagonists such as warfarin
Known or suspected hereditary or acquired bleeding or coagulation disorder
Intervention: Testosterone
Trial phase: Phase 4
ATC code: G03BA03 | G03EA02
SMILES: [H][C@@]12CCC3=CC(=O)CC[C@]3(C)[C@@]1([H])CC[C@]1(C)[C@@H](O)CC[C@@]21[H]
Sex: Male
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 11
Group description: Testosterone 200 mg intramuscular every 2 weeks

Testosterone: Sustanon- 200mg- Intramuscular testosterone every 2 weeks
Eligibility criteria:
Inclusion Criteria:

Type 2 diabetes mellitus.
Serum testosterone 12 nmol/L or less on two consecutive samples taken on different days and symptoms compatible with hypogonadism.

Peripheral vascular disease as defined by

previous diagnosis by a specialist vascular surgeon OR
ABPI less than 0.92 and ischaemic leg pain (claudication or rest pain) or distal complications (non-healing arterial foot ulcer or gangrene).
Agreement to maintain antihypertensive and antilipid treatments at prior doses during 3 month duration of study.
Ability to give written informed consent after verbal and written explanation in the English language.
Ability to comply with all study requirements.

Exclusion Criteria:

Current or previous breast cancer.
Current or previous prostate cancer.
Raised prostate specific antigen (PSA) or abnormal per rectal examination unless prostate cancer excluded after specialist urology opinion.
Severe symptoms of benign prostatic hypertrophy ('prostatism')
Treatment with testosterone in the 3 months prior to the trial.
Investigational drug treatment in the 3 months prior to the trial.
Intervention: Ketamine
Trial phase: Phase 2
ATC code: N01AX03 | N01AX14 | N06AX27
SMILES: CNC1(c2ccccc2Cl)CCCCC1=O
Sex: All
Age groups: Child | Adult | Older Adult
Healthy volunteers: No
Participants at risk: 20
Group description: Single bolus 0.5mg/kg ketamine IV after induction of anesthesia
Eligibility criteria:
Inclusion Criteria:

All patients presenting for lobectomy either VATS or open.

Exclusion Criteria:

Patients with myocardial infarction in the previous six months,
Patients with a history of psychotic disorder,
Patients with a history of chronic pain syndrome,
Patients with documented previous allergy to ketamine.
Intervention: SODIUM CHLORIDE
Trial phase: Phase 2
ATC code: A12CA01 | B05CB01 | B05XA03 | S01XA03
SMILES: [Cl-].[Na+]
Sex: All
Age groups: Child | Adult | Older Adult
Healthy volunteers: No
Participants at risk: 20
Group description: 0.9 % saline bolus of equivalent volume
Eligibility criteria:
Inclusion Criteria:

All patients presenting for lobectomy either VATS or open.

Exclusion Criteria:

Patients with myocardial infarction in the previous six months,
Patients with a history of psychotic disorder,
Patients with a history of chronic pain syndrome,
Patients with documented previous allergy to ketamine.
Intervention: Brivaracetam
Trial phase: Phase 3
ATC code: N03AX23
SMILES: CCC[C@@H]1CC(=O)N([C@@H](CC)C(N)=O)C1
Sex: All
Age groups: Child | Adult | Older Adult
Healthy volunteers: No
Participants at risk: 359
Group description: A flexible dose of Brivaracetam tablets, administered twice a day, starting with a dose of 20 mg/day and could increase to 50 mg/day, 100 mg/day or 150 mg/day
Eligibility criteria:
Inclusion Criteria:

Subjects were aged from 16 to 70 years, inclusive. Subjects under 18 years of age were only included where legally permitted and ethically accepted
Subjects had well-characterized localization-related Epilepsy or generalized Epilepsy according to the International League Against Epilepsy (ILAE) classification
For subjects suffering from localization-related Epilepsy: subjects had at least 2 Partial-Onset Seizures (POSs) whether or not secondarily generalized per month during the 3 months preceding Visit 1 according to the ILAE classification
For subjects suffering from localization-related Epilepsy: subjects had at least 4 Partial-Onset Seizures (POSs) whether or not secondarily generalized during the 4-week Baseline Period according to the ILAE classification
For subjects suffering from generalized Epilepsy: subjects had at least 2 Type II-seizure days per month during the 3 months preceding Visit 1 according to the ILAE classification
For subjects suffering from generalized Epilepsy: subjects had at least 4 Type II-seizure days during the 4 week Baseline Period according to the ILAE classification
Subjects were uncontrolled while treated by 1 to 3 permitted concomitant Antiepileptic Drugs (AEDs). Vagal nerve stimulation was allowed and was not counted as a concomitant AED

Exclusion Criteria:

For subjects who suffered from localization-related Epilepsy: history or presence of Seizures occurring only in clusters (too frequently or indistinctly separated to be reliably counted) before Visit 2 or occurring only as Type IA non-motor
Subjects with a history or presence of Status Epilepticus during the year preceding Visit 1 or during Baseline
Intervention: Propofol
Trial phase: Phase 4
ATC code: N01AX10
SMILES: CC(C)c1cccc(C(C)C)c1O
Sex: All
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 60
Group description: Propofol give at 0.90 μgml-1 to gauge subject's responses to visual stimuli.

Propofol: A low dose of propofol 0.90 μgml-1, given intravenously while the subject is shown visually stimulating images in an MRI machine.
Eligibility criteria:
Inclusion Criteria:

age b/w 18 and 50
right-handed
minimum of high school education
fluent in English
normal vocabulary

Exclusion Criteria:

any significant medical/psychiatric comorbidity
deficit in vision or hearing that would impede the study
allergies to any of the study drugs, to soybeans, or eggs.
history of head trauma
family history of major psychiatric illness
body mass index > 30 kg/m2
claustrophobia
prior exposure to IAPS pictures
pregnancy
permanent metal objects anywhere in the body
a personal/family history of any porphyria
Intervention: Thiopental
Trial phase: Phase 4
ATC code: N01AF03 | N05CA19 | N05CB01
SMILES: CCCC(C)C1(CC)C(=O)NC(=S)NC1=O
Sex: All
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 60
Group description: Thiopental give at 3.0 μgml-1 to gauge subject's responses to visual stimuli.

Thiopental: A low dose of thiopental 3.0 μgml-1, given intravenously while the subject is shown visually stimulating images in an MRI machine.
Eligibility criteria:
Inclusion Criteria:

age b/w 18 and 50
right-handed
minimum of high school education
fluent in English
normal vocabulary

Exclusion Criteria:

any significant medical/psychiatric comorbidity
deficit in vision or hearing that would impede the study
allergies to any of the study drugs, to soybeans, or eggs.
history of head trauma
family history of major psychiatric illness
body mass index > 30 kg/m2
claustrophobia
prior exposure to IAPS pictures
pregnancy
permanent metal objects anywhere in the body
a personal/family history of any porphyria
Intervention: Melatonin
Trial phase: Phase 1
ATC code: N05CH01
SMILES: COc1ccc2[nH]cc(CCNC(C)=O)c2c1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 4
Group description: 0.15 mg/kg capsules by mouth daily
Eligibility criteria:
Inclusion Criteria:

Breast cancer patients having a unilateral segmental mastectomy, with or without intraoperative lymph node mapping, sentinel node biopsy, and axillary node dissection
Ages >= 40 years
American Society of Anesthesiology (ASA) physical status classification of preoperative functioning) 1-4 levels are acceptable
Willing and able to give written informed consent
Willing and able to complete questionnaires
Not currently taking benzodiazepine medication for insomnia.

Exclusion Criteria:

Autoimmune diseases: rheumatoid arthritis, systemic lupus, or other collagen vascular disease
Alcoholics
Seizure disorder
Thyroid disease
Pregnant or lactating patients (effects not known in pregnancy)
Renal/hepatic failure (if ood urea nitrogen (BUN) or creatinine (Cr) >2.5* Upper limit of normal (ULN); Bili or aspartate aminotransferase (AST) or alanine aminotransferase (ALT)>2.5* ULN)
Dementia/poor compliance
Manic/psychotic patients
Children/adults under 40 yrs
Movement disorders (ex. restless leg syndrome)
Tremor disorder (ex. parkinsonism)
Chronic benzodiazepine use for sleep (>4 times per week )
Designated preop medications including melatonin for sleep
Intervention: MK-0249
Trial phase: Phase 2
SMILES: Cc1nc2cccc(C(F)(F)F)c2c(=O)n1-c1ccc(OCCCN2CCCC2)cc1
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 52
Group description: 10 mg per day of MK-0249 were taken orally for Treatment Period 1 or Treatment Period 2 (depending on the sequence). At any time after 3 days of double-blind treatment if patients who were unable to tolerate 10 mg per day, they were allowed to titrate down to 7 mg per day and remained on 7 mg per day for the remainder of the treatment period.
Eligibility criteria:
Inclusion Criteria:

Patient is clinically stable, on current antipsychotic medication for at least 3 months and current dose for 2 months
Patient has a 6th grade reading level or better
Females are not pregnant, and those who can have children agree to remain abstinent or use acceptable birth control throughout the study
Patient has had a stable living arrangement for at least 3 months prior to study start
Patient is in general good health based on screening assessments
Patient has total Positive and Negative Syndrome Scale (PANSS) score between 36 and 75 at screening and at the first baseline visit
Patient has a Clinical Global Impressions - Severity (CGI-S) score less than or equal to 4 at screening and at the first baseline visit

Exclusion Criteria:

Patient has a major disease/disorder that may interfere with cognitive testing (such as mental retardation) and/or pose a risk upon study participation
Patient has a history of head trauma with loss of consciousness greater than 15 minutes
Patient has had warfarin treatment, MAO inhibitors, clonazepam or clozapine within 1 month of screening
Patient has had ECT treatment within 6 months of screening
Patient requires treatment with antihistamines or certain other medications listed in the protocol
Patient has a history of liver disease that has been active within the last 2 years, or a history of cancer within the past 5 years
Patient has a history of alcohol or drug dependence within the past year or alcohol or drug abuse within 3 months of screening
Intervention: Lente
Trial phase: Phase 4
SMILES: CCC(C)C(NC(=O)CN)C(=O)NC(C(=O)NC(CCC(=O)O)C(=O)NC(CCC(N)=O)C(=O)NC1CSSCC2NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CSSCC(NC(=O)C(CC(C)C)NC(=O)C(CC3C=NC=N3)NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)Cc3ccccc3)C(C)C)C(=O)NCC(=O)NC(CO)C(=O)NC(CC3C=NC=N3)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(C)C(=O)NC(CC(C)C)C(=O)NC(Cc3ccc(O)cc3)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(C(=O)NCC(=O)NC(CCC(=O)O)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(Cc3ccccc3)C(=O)NC(Cc3ccccc3)C(=O)NC(Cc3ccc(O)cc3)C(=O)NC(C(=O)N3CCCC3C(=O)NC(CCCCN)C(=O)NC(C(=O)O)C(C)O)C(C)O)CSSCC(C(=O)NC(CC(N)=O)C(=O)O)NC(=O)C(Cc3ccc(O)cc3)NC(=O)C(CC(N)=O)NC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CCC(N)=O)NC(=O)C(Cc3ccc(O)cc3)NC(=O)C(CC(C)C)NC(=O)C(CO)NC2=O)NC1=O)C(C)C.[Zn]
Sex: All
Age groups: Older Adult
Healthy volunteers: No
Participants at risk: 48
Group description: Individually adjusted dose of insulin NPH once daily
Eligibility criteria:
Inclusion Criteria:

Type 2 diabetes
Insulin naive
Treatment with oral anti-diabetic drugs (OADs) for at least 3 months and not achieving therapeutic targets
HbA1c between 8% - 10.5%

Exclusion Criteria:

Secondary diabetes, MODY (Maturity Onset Diabetes of the Young)
Previous treatment with insulin (except for short-term treatment with insulin for intercurrent illness as judged by the Investigator)
Proliferative retinopathy, maculopathy requiring treatment,
Hypoglycaemia unawareness as judged by the Investigator, recurrent major hypoglycaemia
End stage liver disease (increased liver enzymes 4 fold), end stage renal disease assessed by MDRD (Modification of Diet in Renal Disease) less than 30 ml/min or dialysed patient, acute heart failure, any acute cardiovascular event or cerebrovascular event less than 6 months
Acute disease with poor prognosis
History of alcoholism, drug abuse, or psychiatric disease or personality disorders likely to invalidate voluntary consent or to prevent good compliance with the trial protocol
Mental incapacity, unwillingness or language barrier precluding adequate understanding or co-operation (patients having a score of less than 15 in a previous MMSE (Mini-Mental State Examination) in the last six months) and any conditions as judged by the investigator
Legal incapacity or limited legal capacity (patients under guardianship or curatorship)
Concomitant medication for Alzheimers treatment (Memantine, Anticholinesterasique treatment)
Participation in another clinical trial less than one month before inclusion in this trial
Illness requiring repeated hospitalisation
Known or suspected allergy to the insulin or any compositional component
Anticipated change or new use in concomitant medication known to interfere with glucose metabolism, such as systemic corticotherapy more than 5 mg/day (prednisone)
Any other condition that the Investigator feels would interfere with trial participation or evaluation of results
Terminal illness
Intervention: Imatinib Mesylate
Trial phase: Phase 1 | Phase 2
SMILES: CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 9
Group description: All patients were treated with imatinib mesylate at a mean dosage of 300 mg daily.
Eligibility criteria:
Inclusion Criteria:

Adults with refractory diffuse or limited SSc and any or all of the following: Progressive cutaneous fibrosis, Interstitial lung disease, Pulmonary arterial hypertension, Digital ulcerations.

Exclusion Criteria:

Uncontrolled congestive heart failure, hypertension, or coronary artery disease.

HIV, hepatitis B, and/or hepatitis C infection. Serious infection within the past month. Significant hematologic, renal, or hepatic abnormalities. Concurrent use of intravenous immunoglobulin or cyclophosphamide within 4 weeks of the first treatment dose.

Concurrent use of a biologic agent (ie. etanercept, infliximab, adalimumab, abatacept) within 8 weeks of the first treatment dose (6 months for rituximab).

Women who are pregnant or breastfeeding.
Intervention: Nicardipine
Trial phase: Phase 2
ATC code: C08CA04
SMILES: COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)Cc2ccccc2)C1c1cccc([N+](=O)[O-])c1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 3
Group description: Nicardipine infusion before bypass
Eligibility criteria:
Inclusion Criteria:

All adult (>18 years) patients at Duke University Medical Center (DUMC) presenting for elective aortic surgery scheduled to include a period of deep hypothermic circulatory arrest.

Exclusion Criteria:

Failure to provide written informed consent
Emergency operation
Documented allergy to nicardipine
Intervention: SODIUM CHLORIDE
Trial phase: Phase 2
ATC code: A12CA01 | B05CB01 | B05XA03 | S01XA03
SMILES: [Cl-].[Na+]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 3
Group description: 0.9% saline (placebo) before bypass
Eligibility criteria:
Inclusion Criteria:

All adult (>18 years) patients at Duke University Medical Center (DUMC) presenting for elective aortic surgery scheduled to include a period of deep hypothermic circulatory arrest.

Exclusion Criteria:

Failure to provide written informed consent
Emergency operation
Documented allergy to nicardipine
Intervention: Lactulose
Trial phase: Phase 2
ATC code: A06AD11 | A06AD61
SMILES: OCC1OC(OC2C(CO)OC(O)(CO)C2O)C(O)C(O)C1O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 115
Group description: Lactulose Oral Solution was taken orally at the dose of 20~30ml once every morning after breakfast for continuous 4 weeks. Patients should take lactulose for another 3 months if no severe adverse effect was showed.
Eligibility criteria:
Inclusion Criteria:

meeting the diagnosis of Rome III criteria;
aged from 18 to 75 years old;
no use of medicine for constipation about 2 weeks before the enrollment, no acupuncture treatment for constipation in the previous 3 months, and never joined any other trial in progress in the previous 3 months;
volunteered to join this trial and signed the informed consent form

Exclusion Criteria:

irritable bowel syndrome, organic constipation or secondary constipation caused by endocrine, metabolic, nervous, postoperative diseases, or by drugs;
constipation with serious cardiovascular, hepatic or renal diseases, cognitive dysfunction, aphasia, mental disorders, or illness which affects the cooperation for examination and treatment;
women in gestation or lactation period;
abdominal aortic aneurysm or hepatosplenomegaly, etc.;
blood coagulation disorders or using anticoagulants regularly such as Warfarin and Heparin;
cardiac pacemaker carrier.
Intervention: Malathion
Trial phase: Phase 3
ATC code: P03AX03
SMILES: CCOC(=O)CC(SP(=S)(OC)OC)C(=O)OCC
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 315
Group description: Ceftaroline fosamil was administered in two consecutive 300 mg IV infusions over 30 minutes, every 12 hours (q12h).
Eligibility criteria:
Inclusion Criteria:

Subjects with community-acquired pneumonia requiring:

initial hospitalization or treatment in an emergency room or urgent care setting
infection requiring initial treatment with IV antimicrobial

Exclusion Criteria:

Community-acquired pneumonia suitable for outpatient therapy with an oral antimicrobial agent
Respiratory tract infections not due to community-acquired bacterial pathogens
Infections resistant to ceftriaxone
Any condition requiring concomitant systemic corticosteroids
History of any hypersensitivity or allergic reaction to any ß-lactam antimicrobial
Intervention: FLUTICASONE PROPIONATE
Trial phase: Not Applicable
ATC code: D07AC17 | R01AD08 | R01AD58 | R03BA05
SMILES: [H][C@@]12C[C@@H](C)[C@](OC(=O)CC)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@@]21C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 12
Group description: Treatment with inhaled Corticosteroids
Eligibility criteria:
Inclusion Criteria:

Are between 18 and 70 years of age at the time of signing the informed consent.
Have a diagnosis of asthma according to the Guidelines for the Diagnosis and Management of Asthma and have not been treated with ICS in the previous two months.
Have a PC20 methacholine less than 8 mg/ml.
Have a baseline FEV1 greater or equal to 65% of predicted value (at least 6 hours after bronchodilator).
Are not optimally controlled with short-acting 2 agonists as shown by awakenings due to asthmatic symptoms at least once a week, or regular use of salbutamol on 4 or more occasions per week (excluding exercise prophylaxis) due to asthma symptoms.
ACQ score equal or greater than 2
Have sputum eosinophils less than 2%
Are non smokers or ex-smokers who smoked a maximum of 10 pack/year.

Exclusion Criteria:

Hospitalized patients within the last 3 months
Current or recent (within the last month) symptoms of a cold or flu
Patients with a history of near fatal asthma
Subjects on inhaled corticosteroids, prednisone, long-acting beta 2 agonists, montelukast or theophylline, within 2 months prior to entry into the study.